摘要
目的比较瑞波西汀与西酞普兰治疗抑郁症的疗效和安全性。方法将63例抑郁症患者随机分为两组:瑞波西汀组、西酞普兰组两组疗程均为6周。使用汉密尔顿抑郁量表(HAMD)总分减分值评定临床疗效;副反应量表(TESS)、实验室检查、生命体征等观察药物安全性。于治疗前及治疗第1、2、4、6周末各评定1次。结果治疗6周后,瑞波西汀组HAMD总分减分值为(16.4±5.6),西酞普兰组为(16.2±6.8)分,两组疗效相当,不良反应差异无显著性。结论瑞波西汀治疗抑郁症的疗效与西酞普兰相似,不良反应少而轻,是一种安全有效的抗抑郁药物。
Objective To explore the efficacy and safety of reboxetine in treating depression. Methods A total of 63 patients with depression were randomly divided into reboxetine group （n=32） and citalopram group （n = 31） for the treatment of 6 weeks. The patients were assessed with the Hamilton Depression Scale （HAMD） and Treatment Emergent Symptom Scale （TESS）. Results At the end of six weeks,the total scores of HAMD in reboxetine（16. 4±5. 6） and citalopram （16.2±6.8） group both significantly decreaced. Between two groups,the efficacy（76.6% and 74.2%） and side effects had no significant differences. Conclusion Reboxetine has significant curative efficacy, milder adverse effects and higher safety for treating patients with depression.
出处
《精神医学杂志》
2007年第3期159-160,166,共3页
Journal of Psychiatry
